<?xml version="1.0" encoding="UTF-8" standalone="no"?><document id="DrugDDI.d512" origId="Abarelix"><sentence id="DrugDDI.d512.s0" origId="s0" text="No formal drug/drug interaction studies with Plenaxis? were performed."><entity charOffset="10-14" id="DrugDDI.d512.s0.e0" origId="s0.p0" text="drug" type="drug"/><negationtags>&lt;xcope&gt;&lt;cue&gt;No&lt;/cue&gt; formal drug/drug interaction studies with Plenaxis? were performed&lt;/xcope&gt;.</negationtags></sentence><sentence id="DrugDDI.d512.s1" origId="s1" text="Cytochrome P-450 is not known to be involved in the metabolism of Plenaxis?."><entity charOffset="0-16" id="DrugDDI.d512.s1.e0" origId="s1.p6" text="Cytochrome P-450" type="drug"/><negationtags>&lt;xcope&gt;Cytochrome P-450 is &lt;cue&gt;not&lt;/cue&gt; known to be involved &lt;/xcope&gt; in the metabolism of Plenaxis?.</negationtags></sentence><sentence id="DrugDDI.d512.s2" origId="s2" text="Plenaxis? is highly bound to plasma proteins (96 to 99%)."><entity charOffset="29-44" id="DrugDDI.d512.s2.e0" origId="s2.p18" text="plasma proteins" type="drug"/></sentence><sentence id="DrugDDI.d512.s3" origId="s3" text="Laboratory Tests Response to Plenaxis? should be monitored by measuring serum total testosterone concentrations just prior to administration on Day 29 and every 8 weeks thereafter."><entity charOffset="78-96" id="DrugDDI.d512.s3.e0" origId="s3.p30" text="total testosterone" type="drug"/></sentence><sentence id="DrugDDI.d512.s4" origId="s4" text="Serum transaminase levels should be obtained before starting treatment with Plenaxis? and periodically during treatment."><entity charOffset="6-18" id="DrugDDI.d512.s4.e0" origId="s4.p35" text="transaminase" type="drug"/></sentence><sentence id="DrugDDI.d512.s5" origId="s5" text="Periodic measurement of serum PSA levels may also be considered."/></document>